Teva Investors Dodge Appeal of Class Status in MS Drug Lawsuit

A securities suit against Teva Pharmaceutical Industries Ltd. over drug marketing doesn’t present issues that warrant an immediate appeal of a ruling allowing investors to proceed as a class, the Third Circuit ruled Thursday.

The investors allege Teva attributed the success of Copaxone to legitimate business factors while donating to charities that helped patients purchase the multiple sclerosis treatment. The practice drew a US government suit alleging kickbacks, prompting a stock price decline, the investors say.

Class certification decisions can have a big impact on litigation, effectively making suits disappear or bringing pressure on defendants to settle.

They aren’t typically ...